CytoDyn advances leronlimab to Phase 2 for breast cancer

 CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today its clinical trial with leronlimab in combination with carboplatin for the treatment of metastatic triple-negative breast cancer (mTNBC) has advanced from Phase 1b to a Phase 2 trial. The positive advancement confirms leronlimab will be administered with a 700 mg dosage for patients in the mTNBC trial and Basket trial for 22 solid tumor cancers, as well as compassionate use, eIND and “right-to-try” patients.

Scott Kelly, M.D., CytoDyn’s Chief Medical Officer and Chairman of the Board, commented, “In April of this year, we shared our early findings with the medical and scientific communities at the Triple Negative Breast Cancer Drug Development Digital Summit and the continued progress of our drug candidate, leronlimab. We believe these safety findings are a tremendous step forward for CytoDyn’s oncology program for all tumors that have the potential to be treated with leronlimab. Safety, quality of life, and toxicity are often the greatest concerns of oncology patients and these findings give great hope for those in need.”

https://www.bakersfield.com/ap/news/cytodyn-s-trial-for-metastatic-triple-negative-breast-cancer-demonstrates-safety-with-350-mg/article_cc2ca9f4-21de-56a1-be05-09aa9842b45a.html